Literature DB >> 12509432

Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor.

Pari Malherbe1, Nicole Kratochwil, Frédéric Knoflach, Marie-Thérèse Zenner, James N C Kew, Claudia Kratzeisen, Hans P Maerki, Geo Adam, Vincent Mutel.   

Abstract

A model of the rmGlu1 seven-transmembrane domain complexed with a negative allosteric modulator, 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)- 1,6-dihydro-pyrimidine-5-carbonitrile (EM-TBPC) was constructed. Although the mGlu receptors belong to the family 3 G-protein-coupled receptors with a low primary sequence similarity to rhodopsin-like receptors, the high resolution crystal structure of rhodopsin was successfully applied as a template in this model and used to select residues for site-directed mutagenesis. Three mutations, F801(6.51)A, Y805(6.55)A, and T815(7.39)M caused complete loss of the [(3)H]EM-TBPC binding and blocked the EM-TBPC-mediated inhibition of glutamate-evoked G-protein-coupled inwardly rectifying K(+) channel current and [Ca(2+)](i) response. The mutation W798(6.48)F increased the binding affinity of antagonist by 10-fold and also resulted in a marked decrease in the IC(50) value (4 versus 128 nm) compared with wild type. The V757(5.47)L mutation led to a dramatic reduction in binding affinity by 13-fold and a large increase in the IC(50) value (1160 versus 128 nm). Two mutations, N7474(5.51)A and N7504(5.54)A, increased the efficacy of the EM-TBPC block of the glutamate-evoked [Ca(2+)](i) response. We observed a striking conservation in the position of critical residues. The residues Val-757(5.47), Trp-798(6.48), Phe-801(6.51), Tyr-805(6.55), and Thr-815(7.39) are critical determinants of the EM-TBPC-binding pocket of the mGlu1 receptor, validating the rhodopsin crystal structure as a template for the family 3 G-protein-coupled receptors. In our model, the aromatic ring of EM-TBPC might interact with the cluster of aromatic residues formed from Trp-798(6.48), Phe-801(6.51), and Tyr-805(6.55), thereby blocking the movement of the TM6 helix, which is crucial for receptor activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12509432     DOI: 10.1074/jbc.M211759200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Modulation of bitter taste perception by a small molecule hTAS2R antagonist.

Authors:  Jay P Slack; Anne Brockhoff; Claudia Batram; Susann Menzel; Caroline Sonnabend; Stephan Born; Maria Mercedes Galindo; Susann Kohl; Sophie Thalmann; Liliana Ostopovici-Halip; Christopher T Simons; Ioana Ungureanu; Kees Duineveld; Cristian G Bologa; Maik Behrens; Stefan Furrer; Tudor I Oprea; Wolfgang Meyerhof
Journal:  Curr Biol       Date:  2010-05-27       Impact factor: 10.834

2.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

3.  The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor.

Authors:  Virginie Binet; Carole Brajon; Laurent Le Corre; Francine Acher; Jean-Philippe Pin; Laurent Prézeau
Journal:  J Biol Chem       Date:  2004-05-04       Impact factor: 5.157

Review 4.  Structure and ligand recognition of class C GPCRs.

Authors:  Lei Chun; Wen-hua Zhang; Jian-feng Liu
Journal:  Acta Pharmacol Sin       Date:  2012-01-30       Impact factor: 6.150

Review 5.  Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Authors:  James N C Kew; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-25       Impact factor: 4.530

6.  Common structural requirements for heptahelical domain function in class A and class C G protein-coupled receptors.

Authors:  Virginie Binet; Béatrice Duthey; Jennifer Lecaillon; Claire Vol; Julie Quoyer; Gilles Labesse; Jean-Philippe Pin; Laurent Prézeau
Journal:  J Biol Chem       Date:  2007-02-19       Impact factor: 5.157

Review 7.  Emerging paradigms in GPCR allostery: implications for drug discovery.

Authors:  Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

Review 8.  The impact of GPCR structures on pharmacology and structure-based drug design.

Authors:  Miles Congreve; Fiona Marshall
Journal:  Br J Pharmacol       Date:  2009-11-13       Impact factor: 8.739

9.  Ctr9, a Protein in the Transcription Complex Paf1, Regulates Dopamine Transporter Activity at the Plasma Membrane.

Authors:  Stéphanie De Gois; Patrick Slama; Nicolas Pietrancosta; Amaia M Erdozain; Franck Louis; Caroline Bouvrais-Veret; Laurent Daviet; Bruno Giros
Journal:  J Biol Chem       Date:  2015-06-05       Impact factor: 5.157

10.  Glutamate acts as a partial inverse agonist to metabotropic glutamate receptor with a single amino acid mutation in the transmembrane domain.

Authors:  Masataka Yanagawa; Takahiro Yamashita; Yoshinori Shichida
Journal:  J Biol Chem       Date:  2013-02-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.